Compare TG Therapeutics Inc (TGTX) vs Tenaris S.A. American Depositary Shares (TS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Tenaris S.A. American Depositary Shares — how do they compare? TG Therapeutics Inc trades at $54.41 (market cap $8.32B), while Tenaris S.A. American Depositary Shares trades at $57.76 (market cap $29.55B). The key difference: Tenaris S.A. American Depositary Shares is far larger — about 3.6× TG Therapeutics Inc's market cap, and Tenaris S.A. American Depositary Shares pays a 4.09% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Tenaris S.A. American Depositary Shares for 0 Days on average.
| TGTX | TS | |
|---|---|---|
Market Cap | $8.32B | $29.55B |
Volume | 1,285,303 | 755,655 |
Sector | Health | Energy |
52-Week High | $59.06 | $64.02 |
52-Week Low | $26.94 | $34.28 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $8.52B | $27.21B |
Dividend Yield | — | 4.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.34, down 1.68% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results missed expectations. Analyst sentiment is overwhelmingly positive, with 11 buy ratings and a consensus price target of $80.50, while recent news highlights Briumvi's market share gains and potential acquisition interest.
The outlook for TGTX is favorable, driven by Briumvi's expanding multiple sclerosis market share and raised 2026 revenue guidance to $950 million. Key risks include ongoing earnings misses, a high EV/EBITDA ratio of 61.15, and a shareholder litigation investigation. Upside potential remains if the company meets future earnings targets and sustains its growth trajectory.
Tenaris (TS) trades at $58.54, up 0.84% with neutral technical signals and strong fundamental metrics including a P/E of 15.65 and net income margin of 15.88%. Recent earnings beats and a $1.18 dividend support investor confidence, though cash flow trends show modest net outflows. The stock faces near-term headwinds from shipment delays and margin compression as noted in recent analyst reports.
The outlook remains balanced with analyst consensus favoring Buy (57.69%) and a $66.67 price target suggesting 14% upside. Key risks include cyclical energy sector exposure and operational disruptions, but solid profitability and valuation support make TS attractive for dividend and value investors seeking energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Tenaris S.A. American Depositary Shares
Tenaris S.A. manufactures seamless and welded steel pipe products, including casing, tubing, and line pipe, for the oil and gas industry and certain industrial applications. The company operates an integrated production network across 17 countries and offers Rig Direct, its integrated supply-chain service for oilfield customers.
Read more on TS →
